Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

QUADRA Supports Broader Use For Tesaro's PARP Inhibitor Zejula

Apr 24 2018

• By Emily Hayes

OvarianCancer_1200x675

Related Content

Rubraca Ovarian Cancer Maintenance Approval Brings PARP Inhibitor Parity On Broad Indication

Apr 08 2018

Lynparza Poised For Growth With Broad Ovarian Cancer Approval

Aug 18 2017

Tesaro Shakes Up EU PARP Market With Zejula Launches

Nov 22 2017

Related Companies

Tesaro, Inc.

AstraZeneca PLC

Clovis Oncology, Inc.

Roche Holding AG

Merck & Co., Inc.

Additional Topics

Clinical Trials Research & Development Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window